TABLE 1.
Clinical and biochemical characteristics of the study subjects
| Low HDL Subjects (Median IQR) | High HDL Subjects (Median IQR) | Pa | |
|---|---|---|---|
| N (men/women)b | 24 (12/12) | 23 (12/11) | |
| Age (years) | 53 (51–56) | 54 (50–60) | 0.564 |
| Body mass index (kg/m2) | 27.9 (24.3–31.5) | 22.8 (21.4–24.6) | <0.001 |
| Systolic blood pressure (mmHg) | 131 (118–146) | 132 (121–147) | 0.647 |
| Diastolic blood pressure (mmHg) | 81 (75–89) | 81 (75–87) | 0.882 |
| Total cholesterol (mmol/l) | 5.15 (4.55–5.60) | 5.80 (5.30–6.10) | <0.001 |
| HDL cholesterol (mmol/l) | 0.94 (0.86–1.10) | 2.52 (2.12–2.61) | <0.001 |
| LDL cholesterol (mmol/l) | 3.30 (2.87–3.67) | 3.01 (2.68–3.55) | 0.225 |
| Insulin (mU/l) | 9.15 (7.05–10.93) | 6.00 (5.00–7.90) | 0.0015 |
| Triglycerides (mmol/l) | 1.80 (1.23–2.25) | 0.70 (0.60–0.90) | <0.001 |
| apoA-I (mg/dl) | 134 (121–144) | 222 (206–234) | <0.001 |
| apoA-II (mg/dl) | 28.0 (27.0–34.5) | 39.0 (35.0–45.0) | <0.001 |
| apoB (mg/dl) | 124.5 (106.3–135.0) | 99.0 (84.0–109.0) | <0.001 |
| PLTP activity (nmol/ml/h) | 4765 (4109–5549) | 5304 (4798–5810) | 0.058 |
| PLTP mass (µg/ml) | 7.5 (6.4–9.2) | 8.6 (6.8–9.5) | 0.328 |
| CETP activity (nmol/ml/h) | 28 (25–33) | 31 (27–38) | 0.250 |
| TNF-α (ng/l) | 6.5 (4.5–8.2) | 4.7 (4.1–5.8) | 0.038 |
| IL-6 (ng/l) | 1.6 (1.0–2.1) | 1.1 (0.8–2.0) | 0.163 |
| hs-CRP (mg/l) | 1.4 (0.8–2.7) | 0.7 (0.4–1.2) | 0.012 |
| HDL size (nm) | 9.0 (8.8–9.2) | 9.9 (9.7–10.2) | <0.001 |
Abbreviations: Apo, apolipoprotein; CETP, cholesteryl ester transfer protein; hs-CRP, high sensitivity C-reactive protein; IL, interleukin; IQR, interquartile range; PLTP, phospholipid transfer protein; TNF, tumor necrosis factor.
a
P-value from Mann-Whitney U test.
b
apoA-II measurements of three subjects in both low and high HDL-C groups are not available; hence, calculations are based on measurements from the remaining subjects.